Table 1.
Characteristics of treatment groups, antimicrobial choice and antimicrobial treatment duration
| Non-severe (n = 44) | Severe (n = 40) | Significance | |
|---|---|---|---|
| Gender | male 29, female 15 | male 29, female 11 | ns |
| Age, median (range), years | 66 (26–90) | 66 (21–92) | ns |
| CFS, median (range) | 3 (1–7) | 3 (1–7) | ns |
| Antimicrobial choice (n) | cephalosporin (4) | cephalosporin (2) | |
| amoxicillin/clavulanic acid (20) | amoxicillin/clavulanic acid (13) | ||
| piperacillin/tazobactam (18) | piperacillin/tazobactam (19) | ||
| meropenem (1) | meropenem (3) | ||
| anidulafungin (1) | aztreonam (1) | ||
| amoxicillin/clavulanic acid + clarithromycin (6) | levofloxacin (1) | ||
| linezolid (1) | |||
| Antimicrobial duration, median (range), days | 6 (2–14) | 7 (1–14) | ns |
Comparison of non-severe and severe respiratory infection groups. Demographics, antimicrobial prescription and antimicrobial treatment duration are shown. No significant difference between groups is noted.
ns, not significant.